Mr. Paul Reid:

We are at what we have described as the peak of the supply for the vaccination programme. Last week, more than 340,000 vaccines were administered. We have a good supply line for the next two weeks from Pfizer and a committed supply from Moderna. There will be two more weeks of more than 300,000. In July, based on the national immunisation advisory committee's, NIAC, recommendations on what vaccines we can utilise with which age cohorts, we are down to just Pfizer and Moderna's mRNA vaccines, unless and until there is a change regarding the use of Janssen and AstraZeneca vaccines. It would mean that our supply for July would revert back to what had been the projected levels of approximately 190,000 from Pfizer and some from Moderna, coming to just over 200,000 per week and approximately 840,000 for July.

The latter is what was projected and committed to. We had extra supplies for these three weeks because of a process engaged in by the EU to accelerate some of the deliveries from Pfizer from quarter 3 into quarter 2. We did benefit from that. Ultimately, we revert to the projected supply lines in July from the two mRNA vaccines.